.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The EMPOwER phase 3 trial evaluated erenumab in adults with episodic migraine from Asia, the Middle East and Latin America—populations under-represented in many earlier migraine studies. Nine hundred participants were randomised to placebo or monthly erenumab 70 mg or 140 mg for three months. Both doses significantly reduced monthly migraine days and acute medication-use days compared with placebo, with consistent benefits across several secondary outcomes. Safety findings were comparable with placebo and no new signals emerged. The study is clinically valuable because treatment effects were demonstrated across a geographically diverse population more representative of real-world global migraine care. For HCPs, the results support considering CGRP receptor blockade irrespective of ethnicity or geography while still tailoring treatment to individual characteristics. The findings also reinforce the role of patient-reported outcomes such as disability and treatment satisfaction alongside headache-day counts. This is a useful evidence base for IANCON's discussion of contemporary migraine management and the expansion of targeted preventive therapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The EMPOwER phase 3 trial evaluated erenumab in adults with episodic migraine from Asia, the Middle East and Latin America—populations under-represented in many earlier migraine studies. Nine hundred participants were randomised to placebo or monthly erenumab 70 mg or 140 mg for three months. Both doses significantly reduced monthly migraine days and acute medication-use days compared with placebo, with consistent benefits across several secondary outcomes. Safety findings were comparable with placebo and no new signals emerged. The study is clinically valuable because treatment effects were demonstrated across a geographically diverse population more representative of real-world global migraine care. For HCPs, the results support considering CGRP receptor blockade irrespective of ethnicity or geography while still tailoring treatment to individual characteristics. The findings also reinforce the role of patient-reported outcomes such as disability and treatment satisfaction alongside headache-day counts. This is a useful evidence base for IANCON's discussion of contemporary migraine management and the expansion of targeted preventive therapy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
